期刊文献+

奥拉帕尼二聚体杂质的合成

Synthesis of olaparib dimer impurity
下载PDF
导出
摘要 目的研究抗肿瘤药物奥拉帕尼二聚体的合成。方法以(3-氧代-1,3-二氢异苯并呋喃-1-基)膦酸二甲酯为原料,与2-氟-5-甲酰基苯腈反应,再经过水解、环合,最后与哌嗪反应得到奥拉帕尼二聚体杂质,并经过^(1)H-NMR、MS等进行了结构确证。结果合成了奥拉帕尼二聚体杂质,为建立质量标准所需的对照品提供了参考。结论合成奥拉帕尼二聚体杂质使用的各种原料经济易得,合成工艺简单,反应条件温和,反应操作简单,所得产品收率和纯度均较高,合成路线可行。 Objective To study the synthesis of the dimer of the antineoplastic drug Olaparib.Methods Olaparib dimer impurity was obtained from 3-oxo-1,3-dihydroisoben-zofuran-1-ylphosphonic acid by reacting with 2-fluoro-5-formylbenzonitrile,hydrolysis,cyclization,and finally with piperazine,and their structures were confirmed by ^(1)H-NMR and MS.Results Olaparib dimer impurity was synthesized,which provided reference for establishing quality standard.Conclusion Various raw materials for the synthesis of olaparib dimer impurity are economical and easy to obtain.The synthetic process is simple,the reaction conditions are mild,and the operation is simple.The yield and purity of the product are high.The synthetic route is feasible.
作者 许龙 年帅 张浩 曹阳 黄顺旺 曹明成 XU Long;NIAN Shuai;ZHANG Hao;CAO Yang;HUANG Shunwang;CAO Mingcheng(Department of Pharmaceutical Synthesis,Hefei Innovative Pharmaceutical Technology Co.,Ltd.,Hefei,Anhui230088,China)
出处 《安徽医药》 CAS 2023年第8期1540-1542,共3页 Anhui Medical and Pharmaceutical Journal
关键词 奥拉帕尼 药物污染 二聚体杂质 合成 Olaparib Drug contamination Dimer impurity Synthesis
  • 相关文献

参考文献6

二级参考文献26

  • 1窦爱兰,钟化人,郝丽晓.氨苄青霉素钠中有机溶媒残留量的测定与考察[J].药物分析杂志,1996,16(6):382-384. 被引量:8
  • 2Chan S .Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer [J].Br J Cancer 2004, 91: 1420-1424.
  • 3Kolch W Kotwaliwale A Vass K,etal.The role of Raf kinases in ma- lignant transformation[J].Expert Rev Mol Med,2002:l-18.
  • 4K·A·米尼尔,4-[3-(4-环丙烷羰基一哌嗪-1-羰基)-4-氟一苄基]-2H-酞嗪-1-酮的多晶型物:英国W02008/04-7082[P].2008-04-24..
  • 5Keith A.Menear, 4-[3-(4-Cyc 1 --calf- bonyl)-4-fluorobenzyl]-2H-phthalazin-1--one: A Novel Bioavail- able Inhibitor of Poly(ADP-ribose) Polymerase-l[J], J. Med. Chem. 2008, 51, 6581-6591.
  • 6US FDA. FDA LynparzaTM [EB/OL]. [2014-12-19]. http:// www. accessdata, fda.gov/dru-gsat fda_do-cs/label/2014/ 2061621bl.pdf.
  • 7Deeks ED. Olaparib: first global approval [J]. Drugs, 2015, 7S (2) : 231-240.
  • 8White V. FDA grants breakthrough therapy designation to Lynparza in mCRPC [EB/OL]. [2016-01-28]. http://www. europeanpharmaceuticalreview.com/38336/news/industry- news/fda-grants-btd-astrazenecas-lynparza-mcrpc/.
  • 9Martin NMB, Smith GCM, Jackson SP, et al. Phthalazinone derivatives: WO, 2004080976 [P]. 2004-09-23.
  • 10Menear KA, Adcock C, Boulter R, et al. 4-[3-(4- Cyclopropanecarbonylpiperazine- 1 -carbonyl) -4- fluorobenzyl]-2H-phthalazin-l-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1 [J]. J Med Chem, 2008, 51 (20) : 6581-6591.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部